A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Recruiting now · Phase 1/Phase 2
Conditions studied: Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
In brief
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Key facts
- Study ID
- NCT07020221
- Run by
- Verastem, Inc.
- People needed
- 295
- Starts
- 2025-06-24
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-04-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cedars-Sinai Medical Center — Los Angeles, California, United States (enrolling)
- Johns Hopkins University — Baltimore, Maryland, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- University of Michigan — Ann Arbor, Michigan, United States (enrolling)
- Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
- Laura & Isaac Perlmutter Cancer Center at NYU Langone — New York, New York, United States (enrolling)
- Univ of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania, United States (enrolling)
- SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
- MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Huntsman Cancer Institute — Salt Lake City, Utah, United States (enrolling)
- University of Virginia — Charlottesville, Virginia, United States (enrolling)
- Virginia Cancer Specialists — Fairfax, Virginia, United States (enrolling)
- Virginia Mason Medical Center — Seattle, Washington, United States (enrolling)
- Peninsula and Southeast Oncology — Frankston, Victoria, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.